← Back to Screener
Iovance Biotherapeutics, Inc. Common Stock (IOVA)
Price$3.96
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)72.14%
Price vs S&P 500 (4W)15.62%
VGM Score65.41
Market Capitalization$1.83B
All Metrics
Book Value / Share (Quarterly)$1.65
P/TBV (Annual)2.58x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.70
Price vs S&P 500 (YTD)39.25%
Gross Margin (TTM)36.71%
Net Profit Margin (TTM)-123.90%
EPS (TTM)$-0.95
10-Day Avg Trading Volume12.33M
EPS Excl Extra (TTM)$-0.95
EPS (Annual)$-1.09
ROI (Annual)-55.89%
Gross Margin (Annual)34.28%
Cash / Share (Quarterly)$0.72
Revenue Growth QoQ (YoY)44.82%
ROA (Last FY)-42.82%
Revenue Growth TTM (YoY)34.29%
EBITD / Share (TTM)$-0.87
ROE (5Y Avg)-63.72%
Operating Margin (TTM)-127.16%
Cash Flow / Share (Annual)$-0.82
P/B Ratio2.54x
P/B Ratio (Quarterly)2.00x
Net Income / Employee (Annual)$-401,000
EV / Revenue (TTM)5.73x
Net Interest Coverage (TTM)-8.26x
ROA (TTM)-38.77%
EPS Incl Extra (Annual)$-1.09
Current Ratio (Annual)3.20x
Quick Ratio (Quarterly)3.05x
3-Month Avg Trading Volume15.43M
52-Week Price Return124.04%
Revenue / Employee (TTM)$292,900
Tangible BV / Share (Quarterly)$1.03
P/S Ratio (Annual)6.95x
Asset Turnover (Annual)0.29x
52-Week High$5.63
EPS Excl Extra (Annual)$-1.09
CapEx CAGR (5Y)-6.28%
Tangible BV CAGR (5Y)27.99%
26-Week Price Return88.07%
Quick Ratio (Annual)2.74x
13-Week Price Return8.18%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.60x
Enterprise Value$1.64B
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)-17.62%
Revenue / Employee (Annual)$270,300
Pretax Margin (Annual)-149.16%
Cash / Share (Annual)$0.72
3-Month Return Std Dev89.30%
Net Income / Employee (TTM)$-362,900
ROE (Last FY)-55.97%
Net Interest Coverage (Annual)-0.64x
EPS Basic Excl Extra (Annual)$-1.09
Receivables Turnover (TTM)3.74x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.95
ROI (TTM)-50.10%
P/S Ratio (TTM)6.41x
Revenue / Share (Annual)$0.74
Tangible BV / Share (Annual)$1.02
Price vs S&P 500 (52W)95.84%
Year-to-Date Return50.18%
5-Day Price Return-0.24%
EPS Normalized (Annual)$-1.09
ROA (5Y Avg)-48.85%
Net Profit Margin (Annual)-148.38%
Month-to-Date Return22.02%
Cash Flow / Share (TTM)$-1.96
EBITD / Share (Annual)$-1.03
Operating Margin (Annual)-153.08%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-63.61%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.95
P/TBV (Quarterly)3.19x
P/B Ratio (Annual)1.55x
Inventory Turnover (TTM)2.92x
Pretax Margin (TTM)-124.21%
Book Value / Share (Annual)$1.70
Price vs S&P 500 (13W)-1.57%
Beta0.70x
Revenue / Share (TTM)$0.68
ROE (TTM)-50.17%
52-Week Low$1.66
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.19est. -0.15
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.78
3.94
3.94
3.94
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IOVAIovance Biotherapeutics, Inc. Common Stock | C | B | B | $3.96 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Iovance Biotherapeutics is a biopharmaceutical company developing autologous TIL (tumor-infiltrating lymphocyte) cell therapies for solid tumors. The company's personalized approach harnesses patients' own immune cells to target and destroy cancer cells. Iovance is advancing toward U.S. regulatory approval and commercialization of what could be the first autologous T-cell therapy for solid tumor cancers.